BHST vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 28, 2026
BHST
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BHST | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 153.8462 | 9.8522 | GSK |
| PEG Ratio | 0 | 6.1566 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 3.8% | 5.3% | GSK |
| Earnings Growth | 0.0% | -69.5% | BHST |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 31.7/100 | 28.8/100 | BHST |
| Profit Margin | -31.2% | 14.5% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | AVOID NEW MONEY | AVOID NEW MONEY | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BHST
NeutralMixed signals - no dominant trend phase, RSI 51
GSK
NeutralMixed signals - no dominant trend phase, RSI 60
Fundamentals Snapshot
| Metric | BHST | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -5.1 | 10.3 |
| Trailing P/E | — | 16.1 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | 0.6% | 0.7% |
| Operating Margin | -0.3% | 0.3% |
| EPS | -0.48 | 3.17 |
| Dividend Yield | — | 0.04% |